Neurogenetic Diseases

A 23andMe restless legs syndrome result is a population signal, not a diagnosis. Here is what the research on genes, iron, and treatment actually says.

One SACS variant makes a person a carrier, not a patient. The 2024 blood measurement, the Quebec numbers with their dates, and what US and Canadian law covers.

A carrier flag for Usher syndrome is not a diagnosis. A research-grounded guide to PCDH15, CLRN1, real per-pregnancy odds, testing, and 2026 treatment status.

A 23andMe carrier line for limb-girdle muscular dystrophy type 2E is not a diagnosis. Grounded in GeneReviews, NIH, OMIM, and the 2024 Nature Medicine gene-therapy trial, here is what an SGCB carrier result means for you and your family.

A 23andMe carrier line for familial dysautonomia is not a diagnosis. Grounded in the 2001 gene-discovery papers, GeneReviews, NIH, and the 2024 splice-correcting therapy, here is what an ELP1 carrier result means for you and your family.

A research-grounded guide to GJB2 (connexin-26, DFNB1) hearing loss: what a 23andMe carrier flag means, why a failed newborn screen is not a diagnosis, and where gene-therapy research really stands.

A TTR variant on a 23andMe report is a predisposition, not a diagnosis. Here is what it means for you and your family, and where the new FDA-approved treatments stand.

A carrier of an ASPA variant is healthy and will not develop Canavan disease. Here is what the result means for your family, your testing options, and the investigational gene therapies now in trials.

A research-grounded guide to an SMN1 carrier result for spinal muscular atrophy: what one variant means in pregnancy, the real recurrence-risk math, US and Canada testing, and honest treatment status.

A research-grounded guide to a HEXA carrier result for Tay-Sachs: what one variant means, the real recurrence-risk math, US and Canada testing, and honest treatment status.